Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rybak

Showing results (321-330 of 531) with videos related to

Pageof 54
Sort By:
Pharmacotherapy|June 21, 2025
Cefepime-taniborbactam: Ushering in the era of metallo-β-lactamase inhibitionSean R Van Helden, Mohammed Al Musawa, Callan R Bleick, et al.
Antimicrobial Agents and Chemotherapy|October 20, 2020
Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic ModelRazieh Kebriaei, Katherine L Lev, Kyle C Stamper, et al.
Microbiology Spectrum|February 27, 2024
Synergistic bactericidal effects of phage-enhanced antibiotic therapy against MRSA biofilmsAshlan J Kunz Coyne, Kyle Stamper, Callan Bleick, et al.
Journal of Medical Microbiology|March 20, 2008
Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated meticillin-resistant and -susceptible S. aureusEllie J C Goldstein, Diane M Citron, Yumi A Warren, et al.
Diagnostic Microbiology and Infectious Disease|January 23, 2017
Time-kill determination of the bactericidal activity of telavancin and vancomycin against clinical methicillin-resistant Staphylococcus aureus isolates from cancer patientsKenneth Vi Rolston, Weiqun Wang, Lior Nesher, et al.
Antimicrobial Agents and Chemotherapy|April 20, 2011
Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infectionsRavina Kullar, Judy N Chin, David J Edwards, et al.
Antimicrobial Agents and Chemotherapy|July 27, 2011
Characterizing vancomycin-resistant Enterococcus strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic modelMolly E Steed, Celine Vidaillac, Warren E Rose, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 5, 2019
Reply to Koehler et alMaya Beganovic, Megan K Luther, Louis B Rice, et al.
The Journal of Antimicrobial Chemotherapy|October 12, 2014
Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VREBrian J Werth, Katie E Barber, Nikki Tran, et al.
Infectious Diseases and Therapy|August 20, 2014
Evaluation of Daptomycin Non-Susceptible Staphylococcus aureus for Stability, Population Profiles, mprF Mutations, and Daptomycin ActivityMolly E Steed, Ashley D Hall, Hossein Salimnia, et al.
Pageof 54

Showing results (321-330 of 531) with videos related to

Sort By:
Pageof 54
Pharmacotherapy|June 21, 2025
Cefepime-taniborbactam: Ushering in the era of metallo-β-lactamase inhibitionSean R Van Helden, Mohammed Al Musawa, Callan R Bleick, et al.
Antimicrobial Agents and Chemotherapy|October 20, 2020
Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic ModelRazieh Kebriaei, Katherine L Lev, Kyle C Stamper, et al.
Microbiology Spectrum|February 27, 2024
Synergistic bactericidal effects of phage-enhanced antibiotic therapy against MRSA biofilmsAshlan J Kunz Coyne, Kyle Stamper, Callan Bleick, et al.
Journal of Medical Microbiology|March 20, 2008
Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated meticillin-resistant and -susceptible S. aureusEllie J C Goldstein, Diane M Citron, Yumi A Warren, et al.
Diagnostic Microbiology and Infectious Disease|January 23, 2017
Time-kill determination of the bactericidal activity of telavancin and vancomycin against clinical methicillin-resistant Staphylococcus aureus isolates from cancer patientsKenneth Vi Rolston, Weiqun Wang, Lior Nesher, et al.
Antimicrobial Agents and Chemotherapy|April 20, 2011
Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infectionsRavina Kullar, Judy N Chin, David J Edwards, et al.
Antimicrobial Agents and Chemotherapy|July 27, 2011
Characterizing vancomycin-resistant Enterococcus strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic modelMolly E Steed, Celine Vidaillac, Warren E Rose, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 5, 2019
Reply to Koehler et alMaya Beganovic, Megan K Luther, Louis B Rice, et al.
The Journal of Antimicrobial Chemotherapy|October 12, 2014
Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VREBrian J Werth, Katie E Barber, Nikki Tran, et al.
Infectious Diseases and Therapy|August 20, 2014
Evaluation of Daptomycin Non-Susceptible Staphylococcus aureus for Stability, Population Profiles, mprF Mutations, and Daptomycin ActivityMolly E Steed, Ashley D Hall, Hossein Salimnia, et al.
Pageof 54